Oncothyreon Inc (ONTY) was a big mover last session, as the company saw its shares rise nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company, as the stock has gained over 60% in the past one-month time frame.
This biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn’t been in trend either. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Oncothyreon currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked biomedical stocks worth considering are Alexion Pharmaceuticals, Inc. (ALXN), Gilead Sciences Inc. (GILD) and Biogen Idec Inc. (BIIB). While ALXN and GILD sport a Zacks Rank #1 (Strong Buy), BIIB bears a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
ONCOTHYREON (ONTY): Free Stock Analysis Report
ALEXION PHARMACEUTICALS INC (ALXN): Free Stock Analysis Report
GILEAD SCIENCES INC (GILD): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
Zacks Investment Research
- Personal Investing Ideas & Strategies
- Finance Trading